Business Wire

Luxembourg Venture Days to Unite Investors, Startups and Innovators on 16 and 17 October 2024

7.10.2024 16:57:00 CEST | Business Wire | Press release

Share

The second edition of the Luxembourg Venture Days will gather investors, startups, and innovators in a joint summit on 16 and 17 October 2024 at Luxexpo The Box. The annual event is organised by Luxembourg’s innovation agency Luxinnovation and the Luxembourg Private Equity and VC Association (LPEA) under the umbrella of Startup Luxembourg, the country’s network to promote its startup ecosystem. This event offers a unique opportunity for investors and startups to convene, exchange, liaise and explore new strategic and investment horizons.

Luxembourg’s stands as a pivotal financial hub offering various services that attract leading investors and markets around the world. It also built a robust, stable, diversified and thriving economy and is home to around 550 startups and 15 incubators, accelerators, and innovation hubs.

The country boasts a dynamic network of business angels, with a growing number of locally managed venture capital funds.

Luxembourg’s position within a 'Greater Region' (comprising bordering territories of France Germany and Belgium) with 12 million inhabitants, its agility and accessibility, coupled with its business-friendly climate, a pragmatic approach, and an easy access to key decision-makers, makes it a hub, bridge, and springboard for investors and startups in strategic and flourishing domains such as, fintech, space, climate, health, logistics, and mobility. It attracts and invites them to participate in shaping an ecosystem with international reach that inspires innovation and fosters sustainable growth.

The growing number of European unicorns (i.e. startups valued at one billion US dollars or more) shows the progress that the European startup ecosystem has made over the past years. Matchmaking platforms and networks that connect startups and investors are key to maintain and further accelerate this momentum. Luxembourg, as an international business hub and gateway at the heart of Europe, is well positioned to stimulate the interaction between investors and entrepreneurs.

“Luxembourg is a hub, bridge, and springboard for investors and startups to explore opportunities and forge partnerships in strategic domains,” says Sasha Baillie, CEO of Luxinnovation. “The Luxembourg Venture Days will bring together several renowned and high-level events under one roof. For startups, it will be an excellent opportunity to pitch in front of a variety of investors. For investors, it will be a place to team up and find new partners and investments. We are proud to join forces with these main actors to develop our new win-win event formula and foster Luxembourg’s role as a vibrant ecosystem, home and hub for startups and investors.”

“Luxembourg is an important hub for private equity and venture capital investors as it provides an agile and accessible platform for established actors and newcomers who want to keep abreast of developments, explore new avenues, grow their investments, and create added value,” adds Stephane Pesch, CEO of LPEA.”

Registration and agenda: Luxembourg Venture Days.

The highlights of Luxembourg Venture Days 2024:

  • Fit 4 Start pitching sessions (16 + 17 October)
    Pitch of 60 pre-selected startups and selection 20 for the next Fit 4 Start edition
  • LPEA annual Insights Conference (17 October)
    Full-day programme with panels and an exclusive pitching event
  • Keynote and masterclasses for investors and startups by US VC Jillian Manus (16 October)
  • Other pitch, demo, networking, and match-making sessions (16 + 17 October)
    • Tomorrow Street matchmaking breakfast with scale-ups (16 October)
    • Gener8tor Demo Day (17 October)
    • Luxembourg Business Angel Network (LBAN) reverse pitch (17 October)
    • Luxembourg Open Innovation Club (LOIC)/ Luxinnovation Reverse Pitch (16 October)
    • 8 pioneering startups to discover (17 October) – Lunch with eight Influential startups embodying our ecosystem’s potential
  • Presentation of the first-ever Dealroom report on EU-backed startups (16 October)
  • Presentation of the report “Titans of Tech” 2024 by European VC GP Bullhound (16 October)
    • Exclusive VC networking dinner (16 October)
  • Insightful panel discussions (16 + 17 October)
    • The value and benefits of investing in women-led startups (17 October)
    • Navigating term sheet negotiations with investors (16 October)
  • General closing ceremony (17 October) –- -Joint-programme for the large audience with:
    • Keynotes by several leading profiles, including Marjut Falkstedt, CEO of the European Investment Fund
    • Roundtable discussions
    • Announcement of the 20 startups selected for Fit 4 Start #15; followed by a networking cocktail.

About Luxinnovation: as the national innovation agency, we empower companies to innovate today to be ready for tomorrow. We contribute to the development of the economy as a whole by identifying innovation opportunities and fostering collaborative innovation projects that stimulate the development of a sustainable, competitive and digital economy. Set up as an Economic Interest Group, Luxinnovation is supported by the Ministry of the Economy, the Ministry for Research and Higher Education, the Ministry of Foreign and European Affairs, the Luxembourg Chamber of Commerce, the Luxembourg Chamber of Skilled Crafts and FEDIL – The Voice of Luxembourg’s Industry. www.luxinnovation.lu

The Luxembourg Private Equity and Venture Capital Association (LPEA) is the most trusted and relevant representative body of private equity and venture capital practitioners with a presence in Luxembourg. Created in 2010 by a leading group of private equity and venture capital players in Luxembourg, with more than 530 members today, LPEA plays a leading role locally actively promoting PE and VC in Luxembourg. LPEA provides a dynamic and interactive platform which helps investors and advisors to navigate through latest trends in the industry. www.lpea.lu

Startup Luxembourg is the unique brand of Luxembourg's startup ecosystem, aiming at showcasing its players and innovators inside and outside the country. This is a public initiative funded by the Ministry of the Economy and managed by Luxinnovation.
www.startupluxembourg.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241004816914/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye